Onena Medicines Announces Appointment of Dr. Roland Kozlowski to the Board of Directors
August, 2024
Onena Medicines AG is pleased to announce the appointment of Dr. Roland Kozlowski to its Board of Directors. Dr. Kozlowski brings a wealth of expertise in drug discovery, corporate governance, and regulatory oversight that will be instrumental as Onena continues to expand its operations and fulfill its mission to serve patients' needs.
Onena Medicines leads a consortium and wins the Eureka Eurostars grant
March, 2023
Eurostars is the largest international funding programme for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialisation. Onena Medicines led the consortium, consisting of Crown Bioscience, Cancer Research Center Lyon, and HAWK Biosystems. This initiative focuses on countering therapeutic resistance in solid cancers using a monoclonal antibody (mAb-LEFTY1). Initiated in March 2023 with €1.8 million in support, the project aims to develop and expand Crown Bioscience’s organoid panel screening capabilities for the characterization of standard of care compounds and mAb-LEFTY1 drug responses, along with the development of CRISPR-edited drug-resistant organoid models.
CDTI awards the NEOTEC grant to Onena Medicines
November, 2021
Onena Medicines was awarded the highly competitive NEOTEC national grant from the CDTI in Spain. The funding will allow Onena primarily support the development of their anti-LEFTY antibody drug and also to expand their antibody pipeline to new DSIP targets in areas of high unmet medical need. The NEOTEC program aims to finance the start-up of new business projects that require the use of technologies or knowledge developed from research activity.
Onena Medicines joins the BIC Gipuzkoa incubator community
April, 2019
Newly formed Stanford spin-out company, Onena Medicines SL, a biotech company that aims to make antibody medicines that targets Dual SMAD Inhibition Proteins (DSIPs), joined the BIC Gipuzkoa incubator this month. The company, co-founders, Neethan Lobo and Maider Zabala, started the company to translate their discovery that LEFTY proteins drive drug resistance in breast cancer into a therapeutic drug for breast cancer patients.
Onena Medicines closes 3.7M CHF funding round to advance its novel DSIP targeting antibody portfolio
October, 2023
Onena Medicines AG, a cellular reprogramming platform drug discovery company, announced today the closing of a new 3.7M CHF financing round to accelerate the development of its growing Dual SMAD Inhibiting Protein (DSIP) modulating antibody portfolio. DSIPs are a novel class of targets that have breakthrough potential through their potent cellular programming effects on the proliferation and specialization of cells. The funding round consisted of private investments from Avanteca Partners and the Zürcher Kantonalbank into Onena, a BaseLaunch portfolio company. Onena was also awarded a competitive Torres Quevedo grant from the CDTI in Spain to enhance their antibody platform technologies.
Onena Medicines receives the award for best European emerging biotechnology company by the Merck Group and places second in the EIT Health Catapult Biotech competition
March, 2022
This award was presented during the semi-finals of the EIT Health Catapult program, where MERCK acts as one of the sponsors of this program. EIT Health Catapult program participants go through 3 selection rounds over the course of a year, receiving training and mentoring along the way. Onena Medicines won second place, with an award of €20,000, and had the opportunity to pitch in front of approximately 1,500 investors. The EIT Health program recognizes and rewards the best business concepts, accelerated startups to become world-leading companies.
Onena Medicines joins the StartX accelerator of Silicon Valley
January, 2021
StartX is the premier startup community, accelerator, and fellowship program for over 2,500 Stanford founders, offering support without requiring equity. Onena Medicines, a Stanford spin-out company, joined the StartX program to tap into the strongest network of Stanford entrepreneurs, spanning fields such as AI, healthcare, sustainability, and more.
Fomento of San Sebastián awards two grants to Onena Medicines
November, 2019
Fomento of San Sebastian, Spain, awarded Onena Medicines the EKIN+ grant this month. Ekin+ is an acceleration programme for innovative projects that we have been working on since 2014, with the aim of promoting and consolidating innovative business projects in the Basque city. Also, Fomento awarded Onena Medicines the CREACION grant, which is a program that aims to facilitate the launch of new business projects and innovative companies, as well as to promote intrapreneurship, revitalize the entrepreneurial ecosystem and accelerate the growth of companies in Gipuzkoa.
Fundación Biozientziak Gipuzkoa Fundazioa selects Onena Medicines for an investment
March, 2020
After a competitive selection process, Onena Medicines was selected for an investment from the Fundación Biozientziak to accelerate development of their anti-LEFTY1 antibody drug. The Fundación Biozientziak Gipuzkoa Fundazioa is a joint commitment of the Provincial Council of Gipuzkoa and Kutxa Fundazioa that contributes to the development of the biohealth sector through action: identifying business projects linked to biosciences and helping these projects reach the market through providing financial resources and developing awareness and dissemination actions.
Onena Medicines competes in the MassChallenge Boston program
June, 2020
MassChallenge is a global network of zero-equity startup accelerators, and being selected as a finalist is a significant achievement. The 2020 cohort includes 100 early-stage startups, rigorously selected by a community of over 500 expert judges. Onena Medicines joined the program to deepen its ties with the Boston community.
Onena Medicines receives the competitive HAZITEK grant from SPRI
September, 2020
The Hazitek 2020 R&D aid program has been designed to promote Research and Development Projects, both in SMEs, large companies and Basque business associations. The program is made up of non-refundable subsidies to provide the necessary resources for Industrial Research or Experimental Development and its budget is divided into two groups depending on the competitive or strategic nature of the projects. Onena Medicines was awarded an HAZITEK to accelerate the development of their anti-LEFTY antibody drug.
Onena Medicines joins NVIDIA’s Inception Program
August, 2023
Onena Medicines has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements. Onena Medicines intends to work with NVIDIA to develop its computer vision antibody design platform. NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.
Onena Medicines moves its headquarters to Allschwil, Switzerland and receives an investment from the BaseLaunch accelerator program
February, 2022
After a rigorous selection process, Onena Medicines won acceptance into the BaseLaunch accelerator program along with an investment into the company. Onena Medicines will move its headquarters to the new Switzerland Innovation Park in Allschwil while retaining laboratory operations in San Sebastian, Spain.